At a glance
What is the difference between bone mineralisation, turnover and fractures?
Mineralisation adds mineral to bone tissue. Turnover is the continuing removal and replacement of bone. A fracture is a break. A change in one measure does not establish a change in the others.
Did the large vitamin D trial discussed here prevent fractures?
The large fracture study did not demonstrate fewer fractures with the tested supplement regimen. Its participants were not selected for vitamin D deficiency or osteoporosis, a condition that makes bones fragile. The finding does not settle treatment in those groups.
Why can a bone mechanism be real without a supplement trial showing benefit?
The experiments may use different vitamin D forms, genetic changes, ages and outcomes. A change in bone cells or a blood marker cannot substitute for measuring fractures in people.
Read the full article below ↓Bone mineralisation, turnover markers and fractures describe different outcomes. Vitamin D research can produce a clear result for one without establishing the others. Keeping these measurements separate helps explain how strong mechanistic findings can coexist with a null clinical fracture trial.
Mineralisation concerns the matrix receiving mineral
Lieben’s intestinal-VDR model showed accumulation of unmineralised osteoid and impaired cortical mineralisation despite maintained serum calcium. This concerns incorporation of mineral into tissue, not simply the amount of calcium circulating in blood.
The distinction between Vitamin D and Calcium and Vitamin D and Calcium Physiology is useful here. A regulated circulating concentration and accumulated skeletal mineral balance answer different questions. The study’s tissue-specific genetic intervention and mineral-rich dietary rescue do not translate directly into a human dosing rule.
Mature osteoblast/osteocyte VDR deletion was largely normal at baseline but changed the response to high calcitriol. That conditional result also shows why a receptor’s role cannot be described without the cell stage and exposure context.
Turnover markers do not identify every local cell response
CTX reflects a resorption-related process, while osteoclast counts and surfaces describe cells in particular locations. In Lieben’s work, increased serum CTX did not mean that every supplementary osteoclast measurement increased.
Mori’s toxic active-calcitriol experiment used anti-RANKL treatment and osteoblast-lineage VDR deletion to separate signalling from osteoclast output. Anti-RANKL treatment blocked osteoclast formation and CTX responses but did not eliminate every calcium or FGF23 effect. The experiment identifies a specific mechanism, not a direct human fracture estimate.
The distinction between active calcitriol and oral vitamin D3, introduced in Vitamin D Activation, is essential. A short toxic active-hormone exposure cannot be treated as an ordinary supplement trial.
Developmental recruitment is another separate outcome
Masuyama’s juvenile cartilage-VDR model altered vascular and osteoclast recruitment and osteoblast-associated FGF23. Several differences normalised by eight weeks. The study therefore concerns developmental timing as well as cell communication.
It does not identify the unknown cartilage-derived signal, prove a persistent adult phenotype or show that adult mouse growth plates fuse. The associated phosphate changes relate to Vitamin D and Phosphate Regulation, but they do not supply a measured long-term fracture outcome.
Fractures require a clinical or structural endpoint
LeBoff’s VITAL analysis directly assessed incident fractures in 25,871 adults receiving 2,000 IU vitamin D3 daily or placebo. The total-fracture hazard ratio was 0.98, with a 95% confidence interval of 0.89 to 1.08. No significant reduction was established over a median 5.3 years.
The participants were not selected for deficiency or osteoporosis, and severe deficiency was uncommon. The finding does not settle treatment of osteomalacia or every high-risk population. Conversely, mechanistic plausibility cannot replace this randomised comparison for the population studied.
The reported PTH decrease in a subset is a biochemical response, not proof of a fracture benefit or a mediating mechanism. This explanation uses the main-text fracture estimates; unavailable graphics and supplements are not used for subgroup claims.
Conclusion
The relevant question is not whether every bone-related measurement moves in the same direction, but what each experiment actually demonstrates. Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study develops the full comparison. Mineralisation, cellular remodelling and fractures each add evidence, but none should be silently substituted for another.
Primary source and publication details
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.
Related reading
Association between bone turnover markers, BMD and height loss of cemented vertebrae after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures
The purpose is to explore the risk factors among several potential predictors for the height loss of treated vertebral bodies after PVP in patients with OVCF.
Original paper ↗Read more →Association of bone metabolic markers, bone mineral density and clinical characteristics with the occurrence of secondary fractures after PVP/PKP for osteoporotic thoracolumbar fractures: a study on logistic
A retrospective study was conducted on 107 OTF patients treated in our hospital from May 2023 to May 2024.
Original paper ↗Read more →Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients
The primary objective of this study was assessment of possible roles of VDR gene polymorphisms in acromegaly, with regard to the activity of the disease and compared them with a control group.
Original paper ↗Read more →Association of Vitamin D Receptor (VDR) Gene Polymorphisms with Osteoporotic Vertebral Fracture Risk: A Case-Control Study
Background/Objectives: Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, resulting in an increased risk of fragility fractures, particularly vertebral fractures.
Original paper ↗Read more →Association of Vitamin D Receptor (VDR) Gene Polymorphisms with Osteoporotic Vertebral Fracture Risk: A Case-Control Study
Background/Objectives: Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, resulting in an increased risk of fragility fractures, particularly vertebral fractures.
Original paper ↗Read more →Beyond Bone Mineral Density: Real-World Fracture Risk Profiles and Therapeutic Gaps in Postmenopausal Osteoporosis
This study aimed to assess the prevalence of osteoporosis and osteopenia, treatment patterns, and skeletal fragility indicators in a large cohort of postmenopausal women undergoing DXA screening.
Original paper ↗Read more →Bone turnover markers (β-CTX, PINP, ALP) in osteoporosis: correlation with bone loss and fracture risk stratification
Osteoporosis patients exhibited significantly higher β-CTX, PINP, and ALP levels compared to controls (all P < 0.001), alongside lower BMD at both lumbar spine and femoral neck (P < 0.001).
Original paper ↗Read more →Clinical application of bone turnover markers in treating osteoporotic vertebral compression fractures and their role in predicting fracture progression
This study aimed to investigate whether changes in the bone turnover markers (BTMs) during teriparatide therapy for osteoporotic vertebral compression fractures could reflect therapeutic effects by analyzing the relationship between clinical and radiological features and BTMs.
Original paper ↗Read more →Effects of macro: and micronutrient intake on bone mineral density, osteoporotic fracture risk, inflammation, and functional rehabilitation outcomes in orthopedic patients: a systematic review and meta-analysis
The systematic review examined 95 studies which were organized into seven distinct outcome domains.
Original paper ↗Read more →Efficacy of Danshen injection combined with Calcitriol and Calcium/Vitamin-D for the treatment of osteoporotic fractures: A retrospective case-control study
To explore the efficacy of Danshen injection combined with calcitriol and calcium/Vitamin-D in the treatment of osteoporotic fractures.
Original paper ↗Read more →Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study
Here, the two sequential strategies were evaluated in severe osteoporotic patients.
Original paper ↗Read more →Free vitamin D correlate better with bone mineral density and thoracolumbar junction osteoporotic vertebral fractures than serum vitamin D
Therefore, the aim of the present study is to analyse if free vitamin D correlates with BMD and osteoporotic fragile vertebral fractures in the elderly population.
Original paper ↗Read more →Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture
We examined whether patients had received bone mineral density assessment and received anti-osteoporosis therapy during the period of hospitalization.
Original paper ↗Read more →Persistent changes in calcium-regulating hormones and bone turnover markers in living kidney donors more than 20 years after donation
In our recent survey-based study, we found no increased risk of fractures of all types but observed significantly more vertebral fractures in LKDs compared with matched controls.
Original paper ↗Read more →Proteomic profiling of bone tissue reveals distinct pathways in men and women with osteoporosis
This study aimed to identify key proteins and regulatory pathways associated with severe osteoporosis in women and men.
Original paper ↗Read more →Self-perceived Fracture Risk in the Global Longitudinal Study of Osteoporosis in Women: Its Correlates and Relationship with Bone Microarchitecture
The purpose of this study is to examine correlates of self-perceived fracture risk (SPR) and relationships between SPR and subsequent bone density and microarchitecture in the UK arm of the Global Longitudinal Study of Osteoporosis in Women.
Original paper ↗Read more →Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures
This study aimed to evaluate the effectiveness of sequential therapy using short-term anabolic agents followed by antiresorptive treatment on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with osteoporotic hip fractures.
Original paper ↗Read more →The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study
Thus, this study aimed to investigate the real‐world effect of 12 months of romosozumab treatment on BMD increase and identify factors that predict the rate of BMD increase after 12 months of romosozumab treatment.
Original paper ↗Read more →The relationship between cardiometabolic disease and vertebral bone strength, mineral density, and mass in US adults
Lastly, we evaluated whether race, age (≤50 vs >50 years), and menopausal status and hormone therapy use in women modified the association between CMD and the vertebral BCT variables using interaction terms (eg, CMD × Race).
Original paper ↗Read more →The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Original paper ↗Read more →Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs
A total of 26 randomized clinical trials (RCTs) were included in this review.
Original paper ↗Read more →Original sources
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization
Published in The Journal of clinical investigation (2012).
Publication details
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.
The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo
Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.
Publication details
Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
Published in The Journal of clinical investigation (2006).
Publication details
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
Published in The New England journal of medicine (2022).
Publication details
LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.